Last reviewed · How we verify
NCT06577428
A Study of RAY1225 at Different Injection Sites in Participants With Different Body Sizes
Phase 1 trial testing RAY1225 in Healthy in 48 participants. Completed in 8 October 2024.
29 September 2024
Quick facts
| Lead sponsor | Guangdong Raynovent Biotech Co., Ltd |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 48 |
| Start date | 30 July 2024 |
| Primary completion | 29 September 2024 |
| Estimated completion | 8 October 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- RAY1225 — full drug profile →
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Guangdong Raynovent Biotech Co., Ltd — full company profile →
Who can join
Adults 18 to 50, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to compare the amount of RAY1225 that gets into the blood stream and how long it takes the body to get rid of it, when injected under the skin of the upper arm and thigh compared to the abdomen. The study will be conducted in healthy males and females with different body sizes. The tolerability of RAY1225 will be evaluated and information about any side effects experienced will be collected. For each participant, the study will last about 7 weeks, including screening.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06577428
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of RAY1225
Trials testing the same drug.
- NCT07139535 — A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone · Phase 3 · not yet recruiting
- NCT07139548 — A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes · Phase 3 · not yet recruiting
- NCT06893016 — Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight · Phase 3 · recruiting
- NCT07362030 — Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin · Phase 1 · active not recruiting
- NCT06613763 — A Study of RAY1225 in Participants With Impaired Kidney Function · Phase 1 · completed
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Guangdong Raynovent Biotech Co., Ltd trials
Trials by the same sponsor.
- NCT07460284 — A Mass Balance Study Of 14C-RAY1225 Injection In Healthy Chinese Participants · Phase 1 · not yet recruiting
- NCT07229807 — Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A · Phase 3 · active not recruiting
- NCT07229820 — Efficacy and Safety of ZSP1273 in Children 12-17 Years Old With Influenza A · Phase 3 · active not recruiting
- NCT07139535 — A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone · Phase 3 · not yet recruiting
- NCT07139548 — A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06577428 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangdong Raynovent Biotech Co., Ltd
- Last refreshed: 19 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06577428.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing